A Study to Establish a Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population
A Study to Establish a Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population
This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.
Inclusion Criteria:
Exclusion Criteria:
1) Current diagnosis, or history, of any underlying major medical condition determined by the investigator, including but not limited to:
Heart disease
Stroke
Renal disease
Liver disease
Pancreatic disease
Chronic obstructive pulmonary disorder
Bleeding disorders
Hypercalcitoninemia
HIV AIDS
Receiving antibiotic therapy
Suspected infection
Immunosuppression
2) Underwent procedures related to sepsis, or diagnosed with sepsis, within the last 12 months.
3) Current diagnosis of uncontrolled hypertension, hypotension, or diabetes.
4) Diagnosis of bacterial, fungal, or malaria infection within the last 3 months that required antimicrobial treatment.
5 )Experienced severe trauma, surgery, cardiac shock, or severe burn within the previous 3 months requiring medical care.
6) Current diagnosis of cancer within the last 12 months.
7) Received immunotherapy to stimulate or inhibit cytokines within the last 12 months.
8) Hospitalization for more than 24 hours within the last 3 months.
9) Reported as currently pregnant or nursing a child
10) Unable or unwilling to provide the required blood sample for testing.
11) Any other criteria that, in the opinion of the investigator, would render the participant unsuitable for inclusion in the trial.